
Given subcutaneously every 3 months, cemdisiran (Livsayis) is indicated for adults with AChR antibody–positive gMG and requires REMS enrollment.
Here, UCSF's Annie Luetkemeyer talks about new treatments for hepatitis C and what they will do for people with infections.
Here, UCSF's Annie Luetkemeyer talks about new treatments for hepatitis C and what they will do for people with infections.